Comparison of the effects calcitriol and maxacalcitol on secondary hyperparathyroidism in patients on chronic haemodialysis: A randomized propective multicenter trial

Nephrology Dialysis Transplantation

Volumn 19, Issue 8, 2004, Pages 2067-2073

  Hayashi, Matsuhiko ^a   Tsuchiya, Yoshitsugu ^b   Itaya, Yoshiaki ^b   Takenaka, Tsuneo ^c   Kobayashi, Kenji ^d   Yoshizawa, Mamoru ^e   Nakamura, Ryuichi ^f   Monkawa, Toshiaki ^a   Ichihara, Atsuhiro ^a  

^a KEIO UNIVERSITY   (Japan)

^b Tsuchiya Clinic   (Japan)

^c Shinjuku Suimei Clinic   (Japan)

^d Kokubunnji Minamiguchi Clinic   (Japan)

^e Yoshizawa Clinic   (Japan)

^f Nakamura Clinic   (Japan)

Author keywords

Bone alkaline phosphatase; Calcitriol; End stage renal failure; Maxacalcitol; Secondary hyperparathyroidism; Vitamin D analogue

Indexed keywords

22 OXACALCITRIOL; ALKALINE PHOSPHATASE BONE ISOENZYME; CALCITRIOL; PARATHYROID HORMONE; PHOSPHATE; VITAMIN D;

ADULT; ARTICLE; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CLINICAL OBSERVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ELECTROLYTE BLOOD LEVEL; FEMALE; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SECONDARY HYPERPARATHYROIDISM; STATISTICAL SIGNIFICANCE;

ALKALINE PHOSPHATASE; BONE AND BONES; CALCITRIOL; CALCIUM; CALCIUM CHANNEL AGONISTS; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; MALE; MIDDLE AGED; PARATHYROID HORMONE; PHOSPHORUS; PROSPECTIVE STUDIES; RENAL DIALYSIS;

EID: 4344601923     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfh329     Document Type: Article

References (23)

1. Elder G. Pathophysiology and recent advances in the management of renal osteodystrophy. J Bone Miner Res 2002; 17: 2094-2105
2. Silver J, Kilav R, Naveh-Many T. Mechanisms of secondary hyperparathyroidism. Am J Physiol Renal Physiol 2002; 283: F367-F376
3. Brown AJ, Dusso A, Slatopolosky E. Vitamin D. Am J Physiol 1999; 277: F157-F175
4. Goodman WG, Ramirez JA, Belin TA. Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int 1994; 46: 1160-1166
5. Malluche HH, Mawad H, Koszewski NJ. Update on vitamin D and its newer analogues: actions and rationale for treatment in chronic renal failure. Kidney Int 2002; 62: 367-374
6. Hirata M, Endo K, Katsumata K et al. A comparison between 1,25-dihydroxy-22-oxavitamin D3 and 1,25-dihydroxyvitamin D3 regarding suppression of parathyroid hormone secretion and calcaemic action. Nephrol Dial Transplant 2002; 17 [Suppl 10]: 41-45
7. Brown AJ, Ritter CR, Finch JL et al. The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion. J Clin Invest 1989, 84: 728-732
8. Fukagawa M, Kaname S, Igarashi T, Ogata E, Kurokawa K. Regulation of parathyroid hormone synthesis in chronic renal failure in rats. Kidney Int 1991; 39: 874-881
9. Hirata M, Katsumata K, Masaki T et al. 22-Oxacalcitriol ameliorates high-turnover bone and marked osteitis fibrosa in rats with slowly progressive nephritis. Kidney Int 1999; 56: 2040-2047
10. Akizawa T, Kurokawa K, Suzuki M et al. Suppressive effect of 22-oxacalcitriol on secondary hyperparathyroidism of hemodialysis patients. Double-blind comparisons among four doses. J Am Soc Nephrol 1996; 7: 1810 (abstract)
11. Akizawa T, Suzuki M, Akiba T et al. Long-term effect of 1,25-dihydroxy-22-oxavitamin D3 on secondary hyperparathyroidism in haemodialysis patients. One-year administration study. Nephrol Dial Transplant 2002; 17 [Suppl 10]: 28-36
12. Tsukamoto Y, Hanaoka M, Matsuo T et al. Effect of 22-oxacalcitriol on bone histology of hemodialyzed patients with severe secondary hyperparathyroidism. Am J Kidney Dis 2000; 35: 458-464
13. Koshikawa S, Akizawa T, Kurokawa K et al. Clinical effect of intravenous calcitriol administration on secondary hyperparathyroidism. Nephron 2002; 90: 413-423
14. Gao P, Scheibel S, D'Amour P et al. Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1-84: implications for improvement of accurate assessment of parathyroid function. J Bone Miner Res 2001; 16: 605-614
15. Kidney Disease Outcomes Quality Initiative (K/DOQI) Group. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42 [Suppl 3]: S1-S201
16. Quarles LD, Lobaugh B, Murphy G. Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. J Clin Endocrinol Metab 1992; 75: 145-150
17. Indridason OS, Quarles LD, Durham Renal Osteodystrophy Study Group. Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients. Kidney Int 2000; 57: 282-292
18. Kinugasa E, Akizawa T, Takahashi J et al. Effects of 1,25-dihydroxy-22-oxavitamin D3 on parathyroid gland function in haemodialysis patients with secondary hyperparathyroidism. Nephrol Dial Transplant 2002; 17 [Suppl 10]: 20-27
19. Nguyen-Yamamoto L, Rousseau L, Brossard JH, Lepage R, D'Amour P. Synthetic carboxyl-terminal fragments of parathyroidhoromone (PTH) decrease ionized calcium concentration in rats by acting on a receptor different from the PTH/PTH-related peptide receptor. Endocrinology 2001; 142: 1386-1392
20. Monier-Faugere MC, Geng Z, Mawad H et al. Improved assessment of bone turnover by the PTH-(1-84)/large C-PTH fragments ratio in ESRD patients. Kidney Int 2001; 60: 1460-1468
21. Reichel H, Esser A, Roth H-J, Schmidt-Gayk H. Influence of PTH assay methodology on differential diagnosis of renal bone disease. Nephrol Dial Transplant 2003; 18: 759-768
22. Ureña P, De Vernejoul MC. Circulating biochemical markers of bone remodeling in uremic patients. Kidney Int 1999; 55: 2141-2156
23. Ferreira A., Drüeke TB. Biological markers in the diagnosis of the different forms of renal osteodystrophy. Am J Med Sci 2000; 320: 85-89